| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Pharmacology, University of Alberta, Edmonton, Canada
2 Anesthesiology and Pain Medicine, University of Alberta, Edmonton, Canada
3 Pediatrics, University of Alberta, Edmonton, Canada
* To whom correspondence should be addressed. E-mail: sandy.clanachan{at}ualberta.ca.
p38 MAPK and 5'-AMP activated protein kinase (AMPK) are activated by metabolic stresses and are implicated in the regulation of glucose utilization, and ischemia-reperfusion (IR) injury. This study tested the hypothesis that inhibition of p38 MAPK restores the cardioprotective effects of adenosine in stressed hearts by preventing activation of AMPK and the uncoupling of glycolysis from glucose oxidation. Working rat hearts were perfused with Krebs solution (1.2 mM palmitate, 11 mM [3H/14C]glucose and 100 mU/L insulin). Hearts were stressed by transient antecedent IR (2 X 10 min I / 5 min R), prior to severe IR (30 min I / 30 min R). Hearts were treated with vehicle, p38 MAPK inhibitor (SB202190, 10 -µM), adenosine (500 -µM), or their combination prior to severe IR. Following severe IR, the phosphorylation (arbitrary density units) of p38 MAPK and AMPK, rates of glucose metabolism (-µmol/g dry wt/min) and recovery of LV work (Joules) were similar in vehicle-, SB202190- and adenosine-treated hearts. Treatment with SB202190+adenosine versus adenosine alone decreased p38 MAPK (0.03±0.01, n=3 vs 0.48±0.10, n=3, P<0.05) and AMPK (0.00±0.00, n=3 vs 0.26±0.08, n=3 P<0.05) phosphorylation. This was accompanied by attenuated rates of glycolysis (1.51±0.40, n=7 vs 3.95±0.65, n=7, P<0.05), and H+ production (2.12±0.76, n=7 vs 6.96±1.48, n=7, P<0.05), increased glycogen synthesis (1.91±0.25, n=6 vs, 0.27±0.28, n=6, P<0.05), and improved recovery of LV work (0.81±0.08, n=7 vs 0.30±15, n=8, P<0.05). These data indicate that inhibition of p38 MAPK abolishes subsequent phosphorylation of AMPK, and improves the coupling of glucose metabolism, thereby restoring adenosine-induced cardioprotection.
This article has been cited by other articles:
|
|
 |
|
  R. M. Osipov, C. Bianchi, J. Feng, R. T. Clements, Y. Liu, M. P. Robich, H. P. Glazer, N. R. Sodha, and F. W. Sellke Effect of Hypercholesterolemia on Myocardial Necrosis and Apoptosis in the Setting of Ischemia-Reperfusion Circulation, September 15, 2009; 120(11_suppl_1): S22 - S30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. L. Folmes, C. S. Wagg, M. Shen, A. S. Clanachan, R. Tian, and G. D. Lopaschuk Suppression of 5'-AMP-activated protein kinase activity does not impair recovery of contractile function during reperfusion of ischemic hearts Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H313 - H321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-H. Kan, J.-T. Hsu, Z.-F. Ba, M. G. Schwacha, J. Chen, M. A. Choudhry, K. I. Bland, and I. H. Chaudry p38 MAPK-dependent eNOS upregulation is critical for 17{beta}-estradiol-mediated cardioprotection following trauma-hemorrhage Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2627 - H2636. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Omar, H. Fraser, and A. S. Clanachan Ischemia-induced activation of AMPK does not increase glucose uptake in glycogen-replete isolated working rat hearts Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1266 - H1273. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
